All In Biotech

Drug Trial Radar · NCT02665416

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

An Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination With Vanucizumab (Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody, Part I) or Bevacizumab (Anti-VEGF Monoclonal Antibody, Part II) in Patients With Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

94

Actual

Start

Jan 25, 2016

Primary completion

Oct 30, 2019

Study completion Oct 30, 2019

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 27, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, two-part study is designed to assess the safety, PK, PD, and therapeutic activity of Selicrelumab in combination with vanucizumab or bevacizumab in participants with metastatic solid tumors not amenable to standard treatment. Part I (dose escalation) is designed to establish the maximum tolerated dose (MTD) of Selicrelumab in this combination. Part II (expansion) is intended to characterize the safety and tolerability of Selicrelumab in combination with bevacizumab among indication-specific cohorts and to confirm the recommended dose.

Conditions

  • Advanced/Metastatic Solid Tumors

Interventions

  • SelicrelumabDrug

    Selicrelumab will be provided as concentrate for solution to be administered via SC injection

  • VanucizumabDrug

    Vanucizumab will be provided as solution to be administered via IV infusion.

  • BevacizumabDrug

    Bevacizumab will be administered via IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
  2. MTD of Selicrelumab in Combination With VanucizumabTime frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
  3. Recommended Phase II Dose of Selicrelumab in Combination With VanucizumabTime frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
  4. Percentage of Participants With Adverse Events (AEs)Time frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
  5. Part II: Clinical Activity of SC Selicrelumab in Combination with Bevacizumab as Assessed by Response Evaluation in Solid Tumors, Version 1.1 (RECIST v1.1)Time frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
  6. Part II: Percentage of Participants With Best Overall Response per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) CriteriaTime frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
  7. Part II: Duration of Objective Response per RECIST v1.1 CriteriaTime frame: TBaseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
  8. Part II: Percentage of Participants With Disease Control per RECIST v1.1 CriteriaTime frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)
  9. Part II: Progression-free Survival (PFS) per RECIST v1.1 CriteriaTime frame: Baseline until Participant's discontinuation or death, whichever occurs first, as per schedule in the description (up to approximately 42 months)

Locations

16 sites in 7 countries. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Univ of CO Health Science Ctr

    Denver, Colorado

  • Yale Cancer Center; Medical Oncology

    New Haven, Connecticut

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • University Health Network; Princess Margaret Hospital; Medical Oncology Dept

    Toronto, Ontario, Canada

  • Rigshospitalet; Onkologisk Klinik

    København Ø, Denmark

  • Irccs Ospedale San Raffaele;Oncologia Medica

    Milan, Lombardy, Italy

  • Antoni van Leeuwenhoek Ziekenhuis

    Amsterdam, Netherlands

  • Erasmus Medisch Centrum

    Rotterdam, Netherlands

  • Hospital del Mar; Servicio de Oncologia

    Barcelona, Spain

  • Hospital Univ Vall d'Hebron; Servicio de Oncologia

    Barcelona, Spain

  • START Madrid. Centro Integral Oncologico Clara Campal; CIOCC

    Madrid, Spain

  • Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia

    Valencia, Spain

  • ICO L'Hospitalet; Servicio de oncologia medica

    L'Hospitalet de Llobregat, Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.